天津招聘

Responsibility:
1.Strategic Sourcing
-Build up sourcing strategy for the category to bring valuable supporting on business activities for all BU.
-Set up preferred vendor pool and implement frame contract.
-Conduct data analysis to optimize category strategy and purchasing process.

2.Vendor Management
-Implement periodical supplier performance assessment
-SRM with strategic suppliers

3.Operation Management
-Ensure purchasing activities 100% compliant.
-Ensure business needs fulfilled on-time-in-full.
-Perform regular PO tracking and status report.

4.Contract Management
-Ensure frame contract with preferred vendors

5.Communication
-Communicate category strategy with stakeholders to make sure business needs fulfilled.
-Set up regular review with key stakeholders for continuously service level increasing.

Requirements:
1.Bachelor degree or above, major in Supply Chain Management, Business Administration, Commerce or similar.
2.At least 5 years working experience in indirect purchasing, including 3 years in MICE category. Experience with MICE service provider is a plus.
3.Strong communication, negotiation and data analysis skill.
4.Category management and strategic sourcing knowledge.
5.Market intelligence of MICE category.
6.Capability for demand management, sourcing and vendor management.
7.Experience in multi-national pharmaceuticals is preferred.
8.Team management experiences is preferred.

    复宏汉霖（*******）是一家国际化的创新生物制药公司，旨在为全球患者提供质高价优的创新生物药，产品覆盖肿瘤、自身免疫性疾病等领域。自2010年成立以来，公司以全球联动、整合创新为产品开发理念，在中国上海、中国台北和美国加州均设有研发中心，具备了协同增效的突出优势。复宏汉霖主要的产品开发策略是仿创结合，从生物类似药起步，逐步开发创新型单抗产品，结合自主开发的抗PD-1和PD-L1单抗，在国内率先推出免疫联合疗法，前瞻性布局了一个多元化、创新单抗及肿瘤免疫联合疗法管线，打造出研究、开发、商业化生产的综合性生物医药全产业链平台。

    截至目前，复宏汉霖已有1个产品成功上市，2个产品获得中国新药上市申请受理，1个产品获得欧盟营销授权申请受理，10个产品、8个联合治疗方案在全球范围内开展20多项临床试验。其中，公司首款重磅产品汉利康？（利妥昔单抗注射液）于2019年2月获国家药监局新药上市注册批准，成为中国***获批上市的生物类似药。HLX03（阿达木单抗注射液）与HLX02（注射用曲妥珠单抗）已获国家药监局新药上市申请受理，现已纳入优先审评程序。HLX02相继在中国大陆、乌克兰、欧盟波兰和菲律宾全面启动国际多中心3期临床试验，成为国内***开展国际多中心3期临床研究的生物类似药，并于2019年6月获欧洲药品管理局营销授权申请受理。此外，公司已陆续就HLX10（抗PD-1单抗）与自有产品HLX04（贝伐珠单抗生物类似药）、HLX07（抗EGFR单抗）以及化疗联用开展多项肿瘤免疫联合疗法，在全球范围内开展多个临床研究。